Autophagy Maintenance (AUTOMAIN)

This study is testing whether adding two repurposed drugs — hydroxychloroquine (an anti-malarial) and metformin (a diabetes medication) — to standard bevacizumab maintenance therapy can help prevent ovarian cancer from coming back after chemotherapy. **You may be eligible if...** - You have high-grade serous ovarian, fallopian tube, or primary peritoneal cancer that came back but is still sensitive to platinum-based chemotherapy (meaning your cancer was in remission for at least 6 months after your last platinum chemo) - You completed your most recent platinum-based chemo 3–8 weeks ago - You received at least 3 doses of bevacizumab during chemotherapy and plan to continue it - Your cancer responded (partially or completely) to the most recent chemotherapy - You are 18 or older with acceptable blood counts, liver, and kidney function **You may NOT be eligible if...** - Your cancer did not respond to platinum chemotherapy - You have serious heart disease or poorly controlled blood pressure - You are currently in another clinical trial - You have a condition such as G6PD deficiency, porphyria, or myasthenia gravis - You have a high cardiovascular risk score and cannot safely stop statin medications - You are pregnant or planning to become pregnant Talk to your doctor to see if this trial is right for you.